Biotechnology's "C"-Saw Year: Cialis Boosts Icos, Coviracil Costs Triangle

Icos' upcoming NDA filing for the erectile dysfunction agent Cialis looks like the kind of new product milestone that is playing well with biotech investors heading into 2001.